Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 1:07 PM ET

Healthcare Providers and Services

Company Overview of The General Hospital Corporation

Company Overview

The General Hospital Corporation operates as a general hospital in Boston. It offers services in the areas of allergy and immunology, blood, cancer, circulatory, dermatology, digestive, heart, infectious diseases, kidneys, lung, obstetrics and gynecology, psychiatry, rheumatology, surgery, and urology; bones, muscles, and joints; brain, spine, and nervous system; endocrine, diabetes, and metabolism; and mouth, teeth, and face. The company also provides patient and family support services, such as billing and insurance, child care, emotional and support programs, executive health, international patient, medical interpreter, medical records, mind body medicine, nursing, nutrition, patient and ...

55 Fruit Street

Boston, MA 02114

United States

Founded in 1811

Phone:

617-726-2000

Fax:

617-726-3661

Key Executives for The General Hospital Corporation

Chief of Dermatology Service, Director of Melanoma Program for Mgh Cancer Center and Director of Cutaneous Biology Research Center
Head of Cimit Programme
Chairman of the Chiefs' Council
Age: 85
Chief of Molecular Biology
Compensation as of Fiscal Year 2015.

The General Hospital Corporation Key Developments

PTC Therapeutics, Inc. Signs Licensing Agreement with Massachusetts General Hospital for Treatment of Rare Genetic Disorders Resulting from Pre-mRNA Splicing Defects

PTC Therapeutics Inc. has entered into an exclusive worldwide license agreement with Massachusetts General Hospital (MGH) for the treatment of rare genetic disorders resulting from pre-mRNA splicing defects. Both the companies are based in US. Under the terms of the transaction, PTC gains a license to compounds that modulate alternative splicing of the IKBKAP pre-mRNA, the predominant cause of familial dysautonomia (FD), also known as Riley-Day syndrome, a rare life-threatening genetic disorder. PTC will pay an upfront license fee, make payments upon completion of certain development and commercialization milestones, as well as royalties on worldwide product sales. It will fund collaborative research and licensing activities, as well as be responsible for the development and commercialization of products arising from the collaboration.

PTC Therapeutics and Massachusetts General Hospital Collaborate on Rare Disease Research

PTC Therapeutics, Inc. entered into a research collaboration with Massachusetts General Hospital (MGH) for the treatment of rare genetic disorders resulting from pre-mRNA splicing defects. The collaboration reflects both parties' commitment to improving the lives of those who suffer from rare and neglected diseases. Under the terms of the agreement, PTC gains an exclusive worldwide license to compounds that modulate alternative splicing of the IKBKAP pre-mRNA the predominant cause of familial dysautonomia (FD), also known as Riley-Day syndrome, a rare life-threatening genetic disorder. PTC will pay an upfront license fee, make payments upon successful completion of certain development and commercialization milestones, as well as royalties on worldwide product sales. PTC will fund collaborative research and licensing activities, as well as be responsible for the development and commercialization of products arising from the collaboration.

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital

Neon Therapeutics announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline. The work of Neon Therapeutics co-founders Catherine J. Wu, M.D., at the Broad Institute and Dana-Farber Cancer Institute, Nir Hacohen, Ph.D., at the Broad Institute and Massachusetts General Hospital, and Ed Fritsch, Ph.D., at the Broad Institute and Dana-Farber Cancer Institute, led to the development of a personalized neoantigen vaccine, which is the foundation for Neon Therapeutics' proprietary lead compound, NEO-PV-01. The project was originated and led by the Broad Institute and was philanthropically funded in part by the Blavatnik Family Foundation. Dana-Farber Cancer Institute is currently enrolling two investigator-initiated trials with additional trials planned. Neon Therapeutics will build upon this research and initiate a company-sponsored clinical trial in 2016.

Similar Private Companies By Industry

Company Name Region
Laredo Texas Hospital Company, L.P. United States
NovaSom, Inc. United States
Dunn Memorial Hospital United States
Cullman Regional Medical Center, Inc. United States
John Fitzgibbon Memorial Hospital, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact The General Hospital Corporation, please visit www.massgeneral.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.